StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.72−0.16 (-8.51%)

Close on Nov 18, 2026Market cap $6.14MP/E –Yield 959.30%

Cadrenal Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Cadrenal Therapeutics's price to book ratio was 1.1× on Nov 11, 2026, against 7.1× a year earlier. Over the last 4 years it ranged from 0.7× to 7.2×, with a median of 3.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.1×−4.0
2025Dec 31, 20255.1×−0.1
2024Dec 31, 20245.2×+4.1
2023Dec 29, 20231.1×–

More Cadrenal Therapeutics figures

See a number that looks wrong?